Physician profile
Vishad Kumar
NPI 1497716575
$6,607.08
in general payments reported to CMS, 2019-2025
34 companies · $1,929 in 2025
The $1,929 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,692 · 2020: $1,532 · 2021: $50.78 · 2022: $151 · 2023: $92.12 · 2024: $159 · 2025: $1,929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,215 · Food and Beverage: $870 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,215.38 |
| Food and Beverage | $870.19 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,445.96 | 2025 | Infinity, Proclaim |
| Kyowa Kirin, INC. | $1,305.00 | 2020 | |
| Abbvie INC. | $750.10 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $271.74 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $214.67 | 2019 | |
| Akcea Therapeutics, INC. | $186.67 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $182.64 | 2019-2020 | |
| Allergan, INC. | $176.23 | 2019 | |
| Acadia Pharmaceuticals INC | $175.34 | 2019-2025 | Nuplazid |
| Biogen, INC. | $155.60 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $140.27 | 2019 | |
| Lilly USA, LLC | $137.50 | 2019-2024 | Amyvid |
| Lundbeck LLC | $124.82 | 2019-2020 | |
| Emd Serono, INC. | $124.23 | 2019 | |
| Supernus Pharmaceuticals, INC. | $112.49 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $94.99 | 2025 | |
| Avanir Pharmaceuticals, INC. | $91.39 | 2019 | |
| Amgen INC. | $90.58 | 2019-2025 | Uplizna |
| Janssen Pharmaceuticals, INC | $84.30 | 2019 | |
| Amneal Pharmaceuticals LLC | $83.94 | 2019-2025 | Crexont |
| Jazz Pharmaceuticals INC. | $81.88 | 2019-2020 | |
| Genentech USA, INC. | $81.77 | 2019-2020 | |
| Genzyme Corporation | $80.98 | 2019 | |
| Pfizer INC. | $77.86 | 2019-2025 | |
| Assertio Therapeutics, INC. | $71.74 | 2019 | |
| Acorda Therapeutics, INC | $62.13 | 2019 | |
| Ge Healthcare | $41.22 | 2019-2021 | |
| Eisai INC. | $40.21 | 2019-2020 | |
| Ucb, INC. | $33.36 | 2019 | |
| Csl Behring | $19.46 | 2019 | |
| Currax Pharmaceuticals LLC | $18.72 | 2019 | |
| Tanabe Pharma America, INC. | $17.98 | 2019 | |
| Zyla Life Sciences, INC. | $16.54 | 2019 | |
| Upsher-Smith Laboratories LLC | $14.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vishad Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.